Creative Biolabs

Anti-programmed cell death protein 1 (anti-PD-1) and anti-cytotoxic T-lymphocyte-associated protein 4 (anti-CTLA-4) monoclonal antibodies (mAbs) have revolutionized anticancer treatment. However, there are still many patients who do not respond or acquire resistance to these treatments. To overcome these limitations of therapeutic antibodies for immune checkpoints, Creative Biolabs offers immune checkpoint targeted small molecule drug development services to assist our customers with immune checkpoint research and drug development goals.

Learn more: Immune Checkpoint Small Molecule Drug Development